Highlights

  • Megaport Limited (ASX:MP1) is shifting toward AI-compute infrastructure with ambitious growth targets and a significant Capital Investment program.
  • Elsight Limited (ASX:ELS) continues expanding its defence and uncrewed-systems opportunity through its Halo connectivity platform.
  • 4DMedical Limited (ASX:4DX) is progressing commercialisation of its lung-imaging technology as US adoption develops.
  • All three companies represent high-growth themes where execution, funding discipline and commercial traction remain critical.

High-growth technology has been one of the most volatile parts of the ASX in 2026, and Megaport Limited (ASX:MP1), Elsight Limited (ASX:ELS) and 4DMedical Limited (ASX:4DX) highlight three very different versions of that opportunity.

Megaport Limited (ASX:MP1) is repositioning toward AI-compute connectivity, with a major investment program supporting future infrastructure growth. Elsight Limited (ASX:ELS) is benefiting from increasing defence and uncrewed-systems Demand through its connectivity technology. 4DMedical Limited (ASX:4DX) is expanding its digital-health platform as US commercialisation progresses.

These businesses operate in different industries, but they share a common investor test: whether structural demand can be converted into repeatable revenue, sustainable margins and long-term commercial value.

Why the High-Growth Technology Sector Is in Focus in September 2026

High-growth technology companies are typically valued on future scale rather than current earnings, which makes them attractive during periods of strong innovation but also more sensitive to changes in sentiment.

In 2026, investors have become increasingly focused on evidence. Large market opportunities remain important, but companies are being judged on commercial traction, funding discipline, Operating Leverage and the pathway toward profitability.

Several structural themes continue supporting the sector:

  • AI infrastructure: Demand for connectivity, computing power and data processing is creating opportunities across technology providers.
  • Defence technology: Governments are increasing investment in autonomous systems and resilient communications.
  • Digital health: Healthcare providers continue adopting technology that improves diagnostics and efficiency.

Macro conditions remain important. Higher interest rates can pressure valuations for companies with Earnings expected further into the future, while currency movements can influence businesses earning Revenue in US dollars.

Why Megaport Ltd. (ASX:MP1) Is in Focus

Megaport Ltd. (ASX:MP1) provides network-as-a-service connectivity, allowing businesses to establish flexible connections between cloud providers, data centres and networks globally.

Its FY2026 result, released in August 2026, showed strong operating momentum. Group revenue increased about 37% to A$312.2 million, while EBITDA reached around A$77.1 million at a Margin of approximately 25%. Gross margin remained strong at around 73%, and the company reported a net cash position of roughly A$407 million.

Annualised Recurring Revenue reached about A$395 million, reinforcing the recurring nature of its connectivity model.

The defining development, however, was Megaport Limited's (ASX:MP1) move into AI-compute infrastructure. The company secured around A$1.3 billion in strategic contract value and outlined a GPU-pool initiative designed to support AI workloads.

FY2027 guidance points to revenue of A$620–730 million, representing a substantial acceleration. However, that opportunity comes with a major increase in capital requirements, with capex guidance of roughly A$1.28–1.38 billion.

The key question for Megaport Limited (ASX:MP1) is whether the AI-compute expansion can generate returns that justify the scale of investment and maintain the company's historically capital-light profile.

Why Elsight Ltd. (ASX:ELS) Is in Focus

Elsight Ltd. (ASX:ELS) provides connectivity and enablement technology for uncrewed systems, with its Halo platform designed to provide resilient communications for drones operating beyond visual line of sight.

Its half-year result to June 2026 showed significant commercial momentum. Revenue reached about US$23.4 million, or roughly A$34 million, close to five times the prior-year level. Second-quarter revenue of about US$11.8 million represented the company’s sixth consecutive record quarter.

The growth has been supported by increasing defence and public-safety demand. Elsight Limited (ASX:ELS) achieved approval on the US DCMA Blue UAS Cleared List, secured a Basic Ordering Agreement with the US Army and continued engagement across US defence procurement pathways.

The company also secured a follow-on order from a US public-safety customer worth about US$2 million and launched its Stealth Business unit with its first western government customer.

These developments have strengthened the commercial opportunity, but the next stage depends on converting a growing pipeline into consistent, repeatable revenue.

For Elsight Limited (ASX:ELS), defence procurement cycles, government adoption and the ability to scale orders remain the main factors investors are monitoring.

Why 4DMedical Ltd. (ASX:4DX) Is in Focus

4DMedical Ltd. (ASX:4DX) is a respiratory-imaging technology company providing software-based lung-imaging analytics to hospitals and imaging centres.

Its FY2026 result, released on 28 August 2026, showed continued commercial progress. Operating Revenue increased to around A$7 million, up roughly 20% year-on-year, while gross margins remained above 90%. Scan volumes continued growing as the company expanded its US commercial footprint.

The company remains in investment mode as it builds commercial scale, but losses have narrowed as revenue expands.

A notable policy development was the introduction in the US Congress of the bipartisan AIR CARE for Vets Act, which would establish a pilot program using functional lung imaging through the Department of Veterans Affairs. The proposal represents policy recognition of the technology opportunity, although implementation remains uncertain.

For 4DMedical Limited (ASX:4DX), the key question is whether growing scan volumes, healthcare adoption and potential reimbursement pathways can support a transition toward profitability.

What Connects These Three Stocks?

Megaport Limited (ASX:MP1), Elsight Limited (ASX:ELS) and 4DMedical Limited (ASX:4DX) are all high-growth technology companies where future scale remains central to the investment case.

Their industries are different, but each is linked to a structural technology theme.

Megaport Limited (ASX:MP1) represents AI connectivity and infrastructure. Elsight Limited (ASX:ELS) represents defence technology and autonomous systems. 4DMedical Limited (ASX:4DX) represents digital healthcare innovation.

The risk profiles are also different. Megaport Limited (ASX:MP1) is the most capital-intensive due to its infrastructure expansion. Elsight Limited (ASX:ELS) depends heavily on defence adoption and contract conversion. 4DMedical Limited (ASX:4DX) remains focused on commercialising medical technology and expanding healthcare adoption.

Investors watch them together because they represent three examples of how emerging technology themes can create large opportunities while still requiring significant execution.

What Could Move These Stocks Next?

  • Megaport Limited: AI-compute deployments, contract conversion, Capital Expenditure progress and delivery against FY2027 guidance.
  • Elsight Limited: Defence and public-safety contracts, US procurement progress, regulatory developments and quarterly revenue growth.
  • 4DMedical Limited: Scan-volume growth, healthcare partnerships, reimbursement progress and commercial adoption.
  • Sector-wide: Interest-rate expectations, technology-sector sentiment and broader AI investment trends.

What Are the Risks?

The risks remain significant across all three businesses.

Megaport Limited (ASX:MP1) faces execution and funding risks associated with a major capital program. The shift toward AI-compute infrastructure introduces questions around investment returns, customer concentration and payback periods.

Elsight Limited (ASX:ELS) remains exposed to government procurement cycles, contract timing and the uneven nature of defence-related revenue. High expectations also increase sensitivity to any slowdown in growth.

4DMedical Limited (ASX:4DX) carries typical commercialisation risks, including adoption rates, reimbursement outcomes, cash requirements and the pace at which healthcare customers integrate new technology.

Common risks include valuation sensitivity, higher interest rates, currency movements and the challenge of converting promising technology into sustainable earnings.

What ASX Investors Should Watch Next

For Megaport Limited (ASX:MP1), the focus is whether the AI-compute expansion can deliver commercial returns while maintaining financial discipline.

For Elsight Limited (ASX:ELS), investors will monitor whether defence demand translates into repeatable orders and whether its growing pipeline converts into sustainable revenue.

For 4DMedical Limited (ASX:4DX), attention remains on scan-volume growth, US commercial expansion and the pathway toward profitability.

Across all three, the key question is whether structural demand themes can move from market opportunity into measurable financial performance. In high-growth technology, execution often becomes the deciding Factor between potential and proven scale.